CDIX Stock Overview
Cardiff Lexington Corporation, together with its subsidiaries, operates in health care business in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cardiff Lexington Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.50 |
| 52 Week High | US$105.26 |
| 52 Week Low | US$1.50 |
| Beta | 0.61 |
| 1 Month Change | 15.38% |
| 3 Month Change | 87.50% |
| 1 Year Change | -0.25% |
| 3 Year Change | -99.26% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDIX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 15.4% | -0.8% | 2.9% |
| 1Y | -0.3% | 1.7% | 22.2% |
Return vs Industry: CDIX underperformed the US Healthcare industry which returned 1.7% over the past year.
Return vs Market: CDIX underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| CDIX volatility | |
|---|---|
| CDIX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDIX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CDIX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 13 | Alex Cunningham | www.cardifflexington.com |
Cardiff Lexington Corporation, together with its subsidiaries, operates in health care business in the United States. The company Healthcare, and Real Estate segments. It also provides tax resolution service to individuals and companies that have federal and state tax liabilities; and a range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves.
Cardiff Lexington Corporation Fundamentals Summary
| CDIX fundamental statistics | |
|---|---|
| Market cap | US$305.52m |
| Earnings (TTM) | US$2.33m |
| Revenue (TTM) | US$11.85m |
130.9x
P/E Ratio25.8x
P/S RatioIs CDIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDIX income statement (TTM) | |
|---|---|
| Revenue | US$11.85m |
| Cost of Revenue | US$3.56m |
| Gross Profit | US$8.29m |
| Other Expenses | US$5.96m |
| Earnings | US$2.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 69.96% |
| Net Profit Margin | 19.70% |
| Debt/Equity Ratio | 93.8% |
How did CDIX perform over the long term?
See historical performance and comparison